

Supplemental material

contents

Table s 1 in-hospital outcomes of different high-sensitive C-reactive protein levels.

Table s 2 logistic analysis of in-hospital major bleeding and hs-CRP quartiles.

Table s 3 logistic analysis of in-hospital any bleeding and hs-CRP quartiles.

Table s 4 logistic analysis of in-hospital major bleeding and continuous hs-CRP.

Table s 5 logistic analysis of in-hospital any bleeding and continuous hs-CRP.

Table s 6 COX analysis of 5-year major bleeding and hs-CRP quartiles.

Table s 7 COX analysis of 5-year any bleeding and hs-CRP quartiles.

Table s 8 logistic analysis of in-hospital major bleeding and hs-CRP (divided by cutoff).

Figure s 1 ROC of predicting in-hospital major bleeding by hs-CRP or CRUSADE.

Figure s 2 ROC of predicting in-hospital any bleeding by hs-CRP or CRUSADE.

Figure s 3 RCS analysis of in-hospital MACE and hs-CRP.

Figure s 4 RCS analysis of in-hospital death and hs-CRP.

Table s 1 in-hospital outcomes of different high-sensitive C-reactive protein levels.

Outcomes, No. (%)	Q1 (n =644)	Q2 (n =645)	Q3 (n =646)	Q4 (n =647)	p value
Any bleeding	76(11.8%)	79(12.2%)	103(15.9%)	121(18.7%)	<.001
Major bleeding	5(0.8%)	8(1.2%)	15(2.3%)	25(3.9%)	<.001
Stroke	2(0.3%)	2(0.3%)	1(0.2%)	6(0.9%)	0.174
Myocardial infarction	0(0.0%)	6(0.9%)	3(0.5%)	3(0.5%)	0.110
Death	1(0.2%)	0(0.0%)	1(0.2%)	8(1.2%)	<.001
MACE	1(0.2%)	6(0.9%)	4(0.6%)	10(1.5%)	0.043

Table s 2 logistic analysis of in-hospital major bleeding and hs-CRP quartiles.

	Univariate analysis			Multivariable analysis		
	OR	95%CI	P value	OR	95%CI	P value
Anemia	1.24	0.71~2.18	0.447	0.55	0.28~1.06	0.073
DAPT	1.44	0.20~10.52	0.722	1.82	0.24~13.96	0.564
Aterial_Access_Site	4.39	2.51~7.66	0.000	4.03	2.20~7.39	0.000
CHF	4.54	2.60~7.94	0.000	2.66	1.41~5.01	0.002
Hs-CRP_group 2 vs 1	1.61	0.52~4.93	0.409	1.34	0.43~4.21	0.615
Hs-CRP_group 3 vs 1	3.03	1.10~8.40	0.033	2.47	0.86~7.10	0.093
Hs-CRP_group 4 vs 1	5.14	1.95~13.50	0.001	3.71	1.35~10.23	0.011
Diagnose	1.33	0.76~2.32	0.317	1.12	0.61~2.04	0.717
Male	2.06	1.18~3.59	0.011	1.72	0.93~3.19	0.083
MDRD	0.98	0.97~0.99	0.000	0.99	0.98~1.00	0.188
Time to procedure 2 vs 1	0.87	0.42~1.76	0.690	0.83	0.39~1.74	0.615
Time to procedure 3 vs 1	1.80	0.96~3.37	0.068	1.15	0.57~2.31	0.699
SBP	1.01	1.00~1.03	0.054	1.01	0.99~1.02	0.305
Tirofiban use	1.22	0.57~2.61	0.610	1.03	0.44~2.41	0.951
Treated lesion 2 vs 1	0.42	0.19~0.93	0.033	0.58	0.24~1.40	0.222
Treated lesion 3 vs 1	0.57	0.27~1.19	0.132	0.71	0.31~1.64	0.424
Warfarin use	0.00	0.00~I	0.988	0.00	0.00~I	0.985
age	1.06	1.03~1.09	0.000	1.03	1.00~1.07	0.080
AF	1.91	0.58~6.26	0.285	1.31	0.37~4.60	0.670
DM	1.96	1.14~3.38	0.015	1.78	0.99~3.19	0.054
hypertension	1.38	0.73~2.59	0.319	0.65	0.32~1.35	0.250
preloading antiplatelet agents (clopigrel or ticagrelor)	0.64	0.37~1.10	0.107	0.76	0.42~1.36	0.352

Table s 3 logistic analysis of in-hospital any bleeding and hs-CRP quartiles.

	Univariate analysis			Multivariable analysis		
	OR	95%CI	P value	OR	95%CI	P value
Anemia	1.43	1.14~1.79	0.002	1.08	0.84~1.40	0.537
DAPT	0.67	0.37~1.21	0.184	0.72	0.39~1.36	0.317
Aterial_Access_Site	3.11	2.41~4.01	0.000	2.93	2.24~3.83	0.000
CHF	1.44	1.08~1.92	0.013	1.08	0.79~1.49	0.634
Hs-CRP_group 2 vs 1	1.04	0.75~1.46	0.805	0.95	0.67~1.35	0.791
Hs-CRP_group 3 vs 1	1.42	1.03~1.95	0.033	1.40	1.00~1.95	0.047
Hs-CRP_group 4 vs 1	1.72	1.26~2.35	0.001	1.40	1.00~1.95	0.049
Diagnose	1.35	1.08~1.69	0.008	1.28	1.01~1.61	0.039
Male	1.31	1.03~1.68	0.027	1.23	0.95~1.61	0.117
MDRD	0.99	0.99~0.99	0.000	0.99	0.99~1.00	0.004
Time to procedure 2 vs 1	0.93	0.72~1.20	0.587	0.94	0.72~1.22	0.629
Time to procedure 3 vs 1	1.03	0.79~1.35	0.816	0.95	0.71~1.27	0.718
SBP	1.00	0.99~1.00	0.220	1.00	0.99~1.00	0.172
Tirofiban use	1.38	1.02~1.87	0.037	1.30	0.94~1.79	0.114
Treated lesion 2 vs 1	0.78	0.55~1.11	0.162	0.92	0.64~1.34	0.675
Treated lesion 3 vs 1	0.71	0.50~1.00	0.049	0.88	0.61~1.27	0.496
Warfarin use	0.48	0.06~3.73	0.485	0.30	0.03~2.64	0.280
age	1.02	1.01~1.03	0.000	1.01	1.00~1.02	0.081
AF	1.03	0.55~1.92	0.932	1.02	0.53~1.97	0.941
DM	0.96	0.76~1.21	0.723	0.90	0.71~1.15	0.418
hypertension	0.91	0.72~1.16	0.455	0.79	0.60~1.03	0.086
preloading antiplatelet agents (clopigrel or ticagrelor)	0.71	0.57~0.88	0.002	0.77	0.61~0.97	0.027

Table s 4 logistic analysis of in-hospital major bleeding and continuous hs-CRP.

	Univariate analysis			Multivariable analysis		
	OR	95%CI	P value	OR	95%CI	P value
Anemia	1.24	0.71~2.18	0.447	0.59	0.31~1.15	0.119
DAPT	1.44	0.20~10.52	0.722	1.67	0.22~12.71	0.623
Aterial_Access_Site	4.39	2.51~7.66	0.000	3.69	2.00~6.80	0.000
CHF	4.54	2.60~7.94	0.000	2.75	1.45~5.19	0.002
Diagnose	1.33	0.76~2.32	0.317	1.13	0.62~2.08	0.691
Male	2.06	1.18~3.59	0.011	1.65	0.89~3.09	0.114
Hs-CRP_	1.02	1.01~1.02	0.000	1.01	1.01~1.02	0.000
MDRD	0.98	0.97~0.99	0.000	0.99	0.98~1.01	0.254
Time to procedure 2 vs 1	0.87	0.42~1.76	0.690	0.85	0.40~1.80	0.672
Time to procedure 3 vs 1	1.80	0.96~3.37	0.068	1.11	0.55~2.28	0.766
SBP	1.01	1.00~1.03	0.054	1.01	1.00~1.03	0.161
Tirofiban use	1.22	0.57~2.61	0.610	0.98	0.40~2.38	0.960
Treated lesion 2 vs 1	0.42	0.19~0.93	0.033	0.53	0.22~1.29	0.163
Treated lesion 3 vs 1	0.57	0.27~1.19	0.132	0.64	0.28~1.49	0.303
Warfarin use	0.00	0.00~1	0.988	0.00	0.00~1	0.986
age	1.06	1.03~1.09	0.000	1.03	1.00~1.07	0.074
AF	1.91	0.58~6.26	0.285	1.19	0.33~4.32	0.792
DM	1.96	1.14~3.38	0.015	1.63	0.90~2.95	0.104
hypertension	1.38	0.73~2.59	0.319	0.63	0.30~1.30	0.211
preloading antiplatelet agents (clopidogrel or ticagrelor)	0.64	0.37~1.10	0.107	0.72	0.40~1.29	0.268

Table s 5 logistic analysis of in-hospital any bleeding and continuous hs-CRP.

	Univariate analysis			Multivariable analysis		
	OR	95%CI	P value	OR	95%CI	P value
Anemia	1.43	1.14~1.79	0.002	1.08	0.84~1.39	0.564
DAPT	0.67	0.37~1.21	0.184	0.73	0.39~1.38	0.336
Aterial_Access_Site	3.11	2.41~4.01	0.000	2.87	2.20~3.75	0.000
CHF	1.44	1.08~1.92	0.013	1.07	0.78~1.48	0.666
Diagnose	1.35	1.08~1.69	0.008	1.27	1.00~1.60	0.046
Male	1.31	1.03~1.68	0.027	1.23	0.94~1.60	0.125
Hs-CRP_	1.01	1.01~1.02	0.000	1.01	1.00~1.01	0.000
MDRD	0.99	0.99~0.99	0.000	0.99	0.99~1.00	0.007
Time to procedure 2 vs 1	0.93	0.72~1.20	0.587	0.94	0.72~1.23	0.651
Time to procedure 3 vs 1	1.03	0.79~1.35	0.816	0.93	0.70~1.25	0.649
SBP	1.00	0.99~1.00	0.220	1.00	0.99~1.00	0.229
Tirofiban use	1.38	1.02~1.87	0.037	1.29	0.94~1.79	0.119
Treated lesion 2 vs 1	0.78	0.55~1.11	0.162	0.92	0.63~1.33	0.641
Treated lesion 3 vs 1	0.71	0.50~1.00	0.049	0.87	0.60~1.26	0.476
Warfarin use	0.48	0.06~3.73	0.485	0.33	0.04~2.84	0.314
age	1.02	1.01~1.03	0.000	1.01	1.00~1.02	0.077
AF	1.03	0.55~1.92	0.932	0.99	0.51~1.91	0.968
DM	0.96	0.76~1.21	0.723	0.89	0.70~1.14	0.362
hypertension	0.91	0.72~1.16	0.455	0.79	0.60~1.03	0.082
preloading antiplatelet agents (clopidogrel or ticagrelor)	1.43	1.14~1.79	0.002	1.08	0.84~1.39	0.564

Table s 6 COX analysis of 5-year major bleeding and hs-CRP quartiles.

	Univariate analysis			Multivariable analysis		
	HR	95%CI	P value	HR	95%CI	P value
Hs-CRP_group 4	3.27	1.59~6.71	0.001	2.44	1.15~5.17	0.020
Hs-CRP_group 3	1.36	0.60~3.11	0.460	1.14	0.49~2.66	0.767
Hs-CRP_group 2	0.91	0.37~2.25	0.844	0.84	0.34~2.09	0.715
Male	1.22	0.70~2.13	0.491	1.03	0.57~1.86	0.918
Diagnose	1.52	0.91~2.54	0.108	1.41	0.83~2.40	0.198
Hypertension	1.51	0.83~2.74	0.178	0.9	0.47~1.74	0.762
DM	1.68	1.02~2.78	0.043	1.47	0.88~2.48	0.145
AF	1.10	0.27~4.51	0.893	0.85	0.20~3.59	0.828
CHF	3.10	1.80~5.33	<0.001	2.01	1.10~3.67	0.024
Anemia 1	1.57	0.95~2.61	0.081	1.06	0.60~1.88	0.839
preloading antiplatelet agents (clopidogrel or ticagrelor)	1.82	1.04~3.21	0.037	1.99	1.12~3.54	0.019
DAPT	2.01	0.28~14.53	0.488	2.48	0.34~18.06	0.369
Tirofiban use	1.95	1.01~3.75	0.047	1.66	0.82~3.36	0.161
Warfarin use	0.00	0.00~I	0.986	0.00	0.00~I	0.981
Aterial Access Site	1.88	1.07~3.30	0.029	1.67	0.93~3.00	0.086
Treated lesion 2 vs 1	0.52	0.27~1.00	0.050	0.57	0.28~1.15	0.114
Treated lesion 3 vs 1	0.34	0.17~0.70	0.003	0.37	0.17~0.79	0.010
Time to procedure 2 vs 1	1.80	1.01~3.22	0.046	1.34	0.71~2.50	0.364
Time to procedure 3 vs 1	0.90	0.47~1.72	0.745	0.90	0.47~1.73	0.754
Age	1.03	1.00~1.05	0.044	1.01	0.98~1.04	0.626
MDRD	0.99	0.98~1.00	0.025	1.00	0.99~1.01	0.869
SBP	1.02	1.01~1.03	0.003	1.02	1.00~1.03	0.018

Table s 7 COX analysis of 5-year any bleeding and hs-CRP quartiles.

	Univariate analysis			Multivariable analysis		
	HR	95%CI	P value	HR	95%CI	P value
Hs-CRP_group 4	1.61	1.24~2.09	<0.001	1.37	1.04~1.80	0.024
Hs-CRP_group 3	1.26	0.96~1.65	0.090	1.20	0.91~1.58	0.190
Hs-CRP_group 2	0.95	0.71~1.26	0.726	0.92	0.69~1.23	0.590
Male	1.24	1.01~1.53	0.042	1.21	0.97~1.51	0.083
Diagnose	1.59	1.32~1.93	<0.001	1.60	1.32~1.94	<0.001
Hypertension	0.96	0.78~1.17	0.669	0.80	0.64~1.01	0.057
DM	1.07	0.88~1.30	0.504	1.07	0.88~1.31	0.501
AF	0.93	0.53~1.65	0.811	0.90	0.50~1.63	0.736
CHF	1.22	0.94~1.58	0.141	0.97	0.74~1.28	0.842
Anemia 1	1.33	1.10~1.61	0.004	1.15	0.93~1.42	0.210
preloading antiplatelet agents (clopidogrel or ticagrelor)	1.37	1.12~1.67	0.002	1.43	1.17~1.74	0.001
DAPT	1.25	0.70~2.22	0.448	1.45	0.81~2.59	0.210
Tirofiban use	1.67	1.28~2.16	<0.001	1.64	1.25~2.15	<0.001
Warfarin use	0.40	0.06~2.83	0.358	0.38	0.05~2.78	0.339
Aterial Access Site	1.19	0.95~1.51	0.131	1.23	0.97~1.56	0.081
Treated lesion 2 vs 1	1.02	0.75~1.39	0.891	1.06	0.77~1.45	0.722
Treated lesion 3 vs 1	0.82	0.60~1.12	0.210	0.82	0.59~1.13	0.223
Time to procedure 2 vs 1	1.20	0.95~1.52	0.126	1.19	0.93~1.52	0.171
Time to procedure 3 vs 1	1.14	0.91~1.42	0.245	1.19	0.96~1.48	0.120
Age	1.01	1.00~1.02	0.019	1.01	1.00~1.02	0.288
MDRD	1.00	0.99~1.00	0.009	1.00	0.99~1.00	0.246
SBP	1.00	1.00~1.01	0.748	1.00	1.00~1.01	0.395

Table s 8 logistic analysis of in-hospital major bleeding and hs-CRP (divided by cutoff).

	Univariate analysis			Multivariable analysis		
	OR	95%CI	P value	OR	95%CI	P value
Anemia	1.24	0.71~2.18	0.447	0.55	0.29~1.06	0.076
DAPT	1.44	0.20~10.52	0.722	1.86	0.24~14.35	0.552
Aterial_Access_Site	4.39	2.51~7.66	0.000	4.04	2.20~7.39	0.000
CHF	4.54	2.60~7.94	0.000	2.70	1.44~5.07	0.002
Hs-CRP	3.30	1.81~6.03	0.000	2.78	1.47~5.27	0.002
Diagnose	1.33	0.76~2.32	0.317	1.15	0.63~2.09	0.649
Male	2.06	1.18~3.59	0.011	1.71	0.92~3.17	0.088
MDRD	0.98	0.97~0.99	0.000	0.99	0.98~1.00	0.204
Time to procedure 2 vs 1	0.87	0.42~1.76	0.690	0.81	0.39~1.71	0.588
Time to procedure 3 vs 1	1.80	0.96~3.37	0.068	1.19	0.59~2.40	0.623
SBP	1.01	1.00~1.03	0.054	1.01	0.99~1.02	0.330
Tirofiban use	1.22	0.57~2.61	0.610	1.06	0.46~2.49	0.885
Treated lesion 2 vs 1	0.42	0.19~0.93	0.033	0.56	0.23~1.36	0.202
Treated lesion 3 vs 1	0.57	0.27~1.19	0.132	0.69	0.30~1.61	0.394
Warfarin use	0.00	0.00~1	0.988	0.00	0.00~1	0.985
age	1.06	1.03~1.09	0.000	1.03	1.00~1.07	0.070
AF	1.91	0.58~6.26	0.285	1.31	0.37~4.61	0.671
DM	1.96	1.14~3.38	0.015	1.83	1.02~3.28	0.044
hypertension	1.38	0.73~2.59	0.319	0.66	0.32~1.35	0.255
preloading antiplatelet agents (clopigrel or ticagrelor)	0.64	0.37~1.10	0.107	0.77	0.43~1.39	0.386

Figure s 1 ROC of predicting in-hospital major bleeding by hs-CRP or CRUSADE.




Figure s 2 ROC of predicting in-hospital any bleeding by hs-CRP or CRUSADE.




Figure s 3 RCS analysis of in-hospital MACE and hs-CRP.




Figure s 4 RCS analysis of in-hospital death and hs-CRP.

